Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE, and BE RADIANT)

Main Article Content

A Blauvelt
KC Duffin
N Magnolo
J Weisman
M Ståhle
D Wilsmann-Theis
M Wang
K Wixted
B Szilagyi
L Puig


bimekizumab, response, speed, psoriasis, moderate to severe, phase 3, clinical trial, BE VIVID




1. Kornmehl H et al. Dermatology 2021;237:151–157

2. Gorelick J et al. Dermatol Ther (Heidelb) 2019;9:785–797

3. Takeshita J et al. J Am Acad Dermatol 2017;76:377–390

4. Blauvelt A et al. J Drugs Dermatol 2020;19:487–492

5. Warren RB et al. N Engl J Med 2021;385:130–141, NCT03412747

6. Reich K et al. Lancet 2021;397:487–498, NCT03370133

7. Reich K et al. N Engl J Med 2021;385:142–152, NCT03536884

8. Gordon KB et al. Lancet 2021;397:475–486, NCT03410992

Most read articles by the same author(s)

1 2 3 > >>